Aoife ODonovan
Overview
Explore the profile of Aoife ODonovan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
2269
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Downey A, Bradley E, Lerche A, ODonovan A, Krystal A, Woolley J
Psychedelic Med (New Rochelle)
. 2025 Mar;
2(2):61-73.
PMID: 40051581
Background: As the field of psychedelic therapy grows, it is vital to consider who can safely engage with psilocybin therapy. In most modern clinical trials of psilocybin therapy, individuals with...
2.
Neylan T, Muratore L, Williams C, Schmitz M, Valdez C, Maguen S, et al.
BMC Psychiatry
. 2025 Feb;
25(1):185.
PMID: 40021975
There are no reported randomized trials testing exercise versus an active comparator for Posttraumatic Stress Disorder (PTSD). This randomized clinical trial assessed the effectiveness of group exercise versus psychoeducation to...
3.
Haft S, Downey A, Raymond-Flesch M, Fernandes-Osterhold G, Bradley E, ODonovan A, et al.
Psychiatry Res
. 2025 Jan;
345:116359.
PMID: 39823947
A lack of diverse and representative participant samples in mental health intervention research perpetuates mental health disparities. This issue has become a salient concern in studies of psychedelic-assisted psychotherapy (PAT),...
4.
Matvey M, Kelley D, Bradley E, Chiong W, ODonovan A, Woolley J
JAMA Psychiatry
. 2025 Jan;
82(3):311-318.
PMID: 39775830
Importance: There is unprecedented clinician, industry, and patient interest in the therapeutic development of psychedelic drugs. This is due to a combination of promising clinical trial results, positive media coverage,...
5.
Nishimi K, Burgin D, ODonovan A
J Psychosom Res
. 2024 Nov;
175:111539.
PMID: 39491282
Objective: Trauma exposure is associated with risk for cardiometabolic disease and mortality, in part through negative psychological sequelae. In contrast, psychological resilience, showing positive psychological health despite experiencing trauma, may...
6.
Meier M, Kantelhardt S, Gurri L, Stadler C, Schmid M, Clemens V, et al.
Eur J Psychotraumatol
. 2024 Jul;
15(1):2379144.
PMID: 39051592
Early adversity increases the risk for mental and physical disorders as well as premature death. Epigenetic processes, and altered epigenetic aging in particular, might mediate these effects. While the literature...
7.
Nishimi K, Chen R, Schmajuk G, Neylan T, ODonovan A
Psychosom Med
. 2024 Jul;
86(8):670-680.
PMID: 38973730
Objective: Experiencing potentially traumatic events across one's lifecourse increases risk for poor physical health outcomes. Existing models emphasize the effects of any lifetime trauma exposure, risk accumulation (multiple traumas over...
8.
Aday J, Horton D, Fernandes-Osterhold G, ODonovan A, Bradley E, Rosen R, et al.
Psychopharmacology (Berl)
. 2024 May;
241(8):1517-1526.
PMID: 38782821
Rationale: Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use disorders and depression. Current models of PAP emphasize the importance...
9.
Sakai K, Bradley E, Zamaria J, Agin-Liebes G, Kelley D, Fish A, et al.
Psychopharmacology (Berl)
. 2024 Apr;
241(8):1617-1630.
PMID: 38687360
Rationale: Treatments with the serotonergic psychedelic psilocybin are being investigated for multiple neuropsychiatric disorders. Because many patients with these disorders use selective serotonin reuptake inhibitors (SSRIs), understanding interactions between psilocybin...
10.
Nishimi K, Neylan T, Bertenthal D, Seal K, ODonovan A
Psychol Med
. 2024 Feb;
54(9):2024-2032.
PMID: 38311905
Background: Psychiatric disorders may be a risk factor for long COVID, broadly defined as COVID-19 conditions continuing three months post-acute infection. In US Veterans with high psychiatric burden, we examined...